IgA1 protease treatment reverses mesangial deposits and hematuria in a model of IgA nephropathy

Journal of the American Society of Nephrology

Volumn 27, Issue 9, 2016, Pages 2622-2629

  Lechner, Sebastian M ^a,b,c,d   Abbad, Lilia ^a,b,c,d   Boedec, Erwan ^a,b,c,d   Papista, Christina ^a,b,c,d   Le Stang, Marie Bénédicte ^a,b,c,d   Moal, Christelle ^a,b,c,d   Maillard, Julien ^a,b,c,d   Jamin, Agnès ^a,b,c,d   Bex Coudrat, Julie ^a,c,d   Wang, Yong ^e   Li, Aiqun ^e   Martini, Paolo G V ^e   Monteiro, Renato C ^a,b,c,d,f   Berthelot, Laureline ^a,b,c,d  

^a INSERM   (France)

^b Faculty of Medicine   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CNRS   (France)

^e Cubist Pharmaceutical   (United States)

^f BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CD11B ANTIGEN; FIBRONECTIN; IGA1 PROTEASE; IMMUNOGLOBULIN A1 PROTEASE; IMMUNOGLOBULIN FC FRAGMENT; PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SCD89 PROTEIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; IGA-SPECIFIC SERINE ENDOPEPTIDASE; IMMUNOGLOBULIN A; SERINE PROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATURIA; IMMUNOGLOBULIN A NEPHROPATHY; IN VITRO STUDY; IN VIVO STUDY; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; UPREGULATION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GLOMERULONEPHRITIS, IGA; MESANGIUM; METABOLISM;

ANIMALS; DISEASE MODELS, ANIMAL; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS, IGA; HEMATURIA; IMMUNOGLOBULIN A; MICE; SERINE ENDOPEPTIDASES;

EID: 84990228386     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015080856     Document Type: Article

References (31)

1. Berger J, Yaneva H, Nabarra B, Barbanel C: Recurrence of mesangial deposition of IgA after renal transplantation. Kidney Int 7: 232-241, 1975
2. Wyatt RJ, Julian BA: IgA nephropathy. N Engl J Med 368: 2402-2414, 2013
3. Mestecky J, Tomana M, Moldoveanu Z, Julian BA, Suzuki H, Matousovic K, Renfrow MB, Novak L, Wyatt RJ, Novak J: Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res 31: 29-37, 2008
4. Tanaka M, Seki G, Someya T, Nagata M, Fujita T: Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy. Clin Dev Immunol 2011: 470803, 2011
5. Launay P, Grossetête B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, Patey-Mariaud de Serre N, Lehuen A, Monteiro RC: Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med 191: 1999-2009, 2000
6. Vuong MT, Hahn-Zoric M, Lundberg S, Gunnarsson I, van Kooten C, Wramner L, Seddighzadeh M, Fernström A, Hanson LÅ, Do LT, Jacobson SH, Padyukov L: Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int 78: 1281-1287, 2010
7. Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PHM, Tamouza H, Jamin A, Bex-Coudrat J, Gestin A, Boumediene A, Arcos-Fajardo M, England P, Pillebout E, Walker F, Daugas E, Vrtosvnik F, Flamant M, Benhamou M, Cogné M, Moura IC, Monteiro RC: Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 209: 793-806, 2012
8. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y,Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119: 1668-1677, 2009
9. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N,Mariat C, Tomino Y, Julian BA, Novak J: Autoantibodies targeting galactosedeficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23: 1579-1587, 2012
10. Berthelot L, Robert T, Vuiblet V, Tabary T, Braconnier A, DraméM, ToupanceO, Rieu P, Monteiro RC, Touré F: Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int 88: 815-822, 2015
11. Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, Monteiro RC: Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 194: 417-425, 2001
12. Moura IC, Arcos-Fajardo M, Sadaka C, Leroy V, Benhamou M, Novak J, Vrtovsnik F, Haddad E, Chintalacharuvu KR, Monteiro RC: Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J AmSoc Nephrol 15: 622-634, 2004
13. Moura IC, Arcos-Fajardo M, Gdoura A, Leroy V, Sadaka C, Mahlaoui N, Lepelletier Y, Vrtovsnik F, Haddad E, Benhamou M, Monteiro RC: Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 16: 2667-2676, 2005
14. Kanamaru Y, Arcos-Fajardo M, Moura IC, Tsuge T, Cohen H, Essig M, Vrtovsnik F, Loirat C, Peuchmaur M, Beaudoin L, Launay P, Lehuen A, Blank U, Monteiro RC: Fc a receptor I activation induces leukocyte recruitment and promotes aggravation of glomerulonephritis through the FcR g adaptor. Eur J Immunol 37: 1116-1128, 2007
15. Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, Roberts ISD, Morando L, Camilla R, Tesar V, Lunberg S, Gesualdo L, Emma F, Rollino C, Amore A, Praga M, Feriozzi S, Segoloni G, Pani A, Cancarini G, Durlik M, Moggia E, Mazzucco G, Giannakakis C, Honsova E, Sundelin BB, Di Palma AM, Ferrario F, Gutierrez E, Asunis AM, Barratt J, Tardanico R, Perkowska-Ptasinska A; VALIGA study of the ERA-EDTA Immunonephrology Working Group: Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 86: 828-836, 2014
16. Ohtake T,OkaM, Maesato K,Mano T, Ikee R, Moriya H, Kobayashi S: Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis. Hypertens Res 31: 387-394, 2008
17. Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K: Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol 15: 700-707, 2011
18. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157-163, 2004
19. Radhakrishnan J, Cattran DC: The KDiGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient. Kidney Int 82: 840-856, 2012
20. Rauen T, Eitner F, Fitzner C, Sommerer C, ZeierM, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U,WitzkeO,GrossO, Vielhauer V, Mann JF, Hilgers RD, Floege J: STOP-IgANInvestigators. NEngl J Med373: 2225-2236, 2015
21. Floege J: Glomerular disease: Efficacy of corticosteroids in high-risk IgA nephropathy. Nat Rev Nephrol 11: 319-320, 2015
22. Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K,Matsushima M, Utsunomiya Y, Ogura M, Yokoo T, Okonogi H, Ishii T, Hamaguchi A, Ueda H, Furusu A, Horikoshi S, Suzuki Y, Shibata T, Yasuda T, Shirai S, Imasawa T, Kanozawa K, Wada A, Yamaji I, Miura N, Imai H, Kasai K, Soma J, Fujimoto S, Matsuo S, Tomino Y; Special IgA Nephropathy Study Group: A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 29: 1546-1553, 2014
23. Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE; Mayo Nephrology Collaborative Group: A controlled trial of fish oil in IgA nephropathy. N Engl J Med 331: 1194-1199, 1994
24. Coppo R, Roccatello D, Amore A, Quattrocchio G, Molino A, Gianoglio B, Amoroso A, Bajardi P, Piccoli G: Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol 33: 72-86, 1990
25. Papista C, Lechner S, Ben Mkaddem S, LeStang M-B, Abbad L, Bex-Coudrat J, Pillebout E, Chemouny JM, Jablonski M, Flamant M, Daugas E, Vrtovsnik F, Yiangou M, Berthelot L, Monteiro RC: Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction. Kidney Int 88: 276-285, 2015
26. Plaut AG: The IgA1 proteases of pathogenic bacteria. Annu Rev Microbiol 37: 603-622, 1983
27. Senior BW,Woof JM: The influences of hinge length and composition on the susceptibility of human IgA to cleavage by diverse bacterial IgA1 proteases. J Immunol 174: 7792-7799, 2005
28. Long S, Phan E, Vellard MC: The expression of soluble and active recombinant Haemophilus influenzae IgA1 protease in E. coli. [published online ahead of print November 30, 2010]. J Biomed Biotechnol doi: 10. 1155/2010/253983
29. Lamm ME, Emancipator SN, Robinson JK, Yamashita M, Fujioka H, Qiu J, Plaut AG: Microbial IgA protease removes IgA immune complexes from mouse glomeruli in vivo: potential therapy for IgA nephropathy. Am J Pathol 172: 31-36, 2008
30. Duchez S, Amin R, Cogné N, Delpy L, Sirac C, Pascal V, Corthésy B, Cogné M: Premature replacement of m with a immunoglobulin chains impairs lymphopoiesis and mucosal homing but promotes plasma cellmaturation. Proc Natl Acad Sci U S A 107: 3064-3069, 2010
31. De Palois F, Beghetto E, Spadoni A, Montagnani F, Felici F, Oggioni MR, Gargano N: Identification of a human immunodominant B-cell epitope within the immunoglobulin A1 protease of Streptococcus pneumoniae. BMC Microbiol 7: 113, 2007